INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Also it is the most common cause of cancer related death in the world [1] .
The pathogenesis of HCC is thought to be established through multiple and various risk factors with complex interaction between them, these factors include: chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), cirrhosis, carcinogen exposure such as aflatoxin B1 (AFB1) excessive alcohol drinking and a variety of genetic factors In Egypt there was a dramatic increase in the incidence of HCC parallels to the increase in incidence of HCV infected cases in the last few years especially genotype-4, which is the predominant genotype in Egypt with approximately (10%-20%) of the population being infected [4] .
Several single nucleotide polymorphism (SNPS)
have been suggested as a risk factors for a variety of cancers including HCC [5] , for multifactorial disease such as HCC, the identification of modifier genes should make it possible to define hepatocarcinogenic risk factors.
A number of studies have been suggested that the cyclin D1 870A allele is associated with susceptibility to various tumors including oral cancer [6] , colorectal cancer [7] and bladder cancer [8, 9] .
Cyclin D1 (CCND1) is involved in the normal cycle regulation and in neoplesia where it is frequently over expressed [10] .
Cyclin D1 plays an important role as it is a key of cell cycle regulatory proteins at the G1/S check point of the cell cycle. Inhibition of CCND1 often, results in cell cycle arrest whereas, overexpression of CCND1 gene may disrupt normal cell cycle control and subsequently, contributes to oncogenesis [11] . Therefore, CCND1 has been regarded as a potential target of tumor therapy [12] .
Cyclin D1 protein is encoded by the CCND1 gene located on chromosome 11q13. Polymorphism in CCND1 with common G to A substitution at nucleotide G870 A in exon 4 of the gene creates different splice variant transcripts cyclin D1a and cyclin D1b through an alternative splicing at G870 creates an optimal splice clonor site of polymorphism [13].
Cyclin D1 and D1b proteins differ in their CooHterminus a region involved in protein degradation, both transcripts encode proteins that contain amino acids which are responsible for the function of cyclin D1 therefore, it has been demonstrated that, transcripit (b) is more likely to bypass the G1/S cell cycle check point which consequently, lead to over accumulation of cyclin D1 in the cell, which result in the propagation of unrepaired DNA damage [14] .
So, CCND1G870A polymerphism may influence the individuals susceptibility for development of certain tumors. So, genotyping analysis using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay to evaluate the distribution of cyclin D1 gene G870A genotypes in patient with HCV. So, early detection of patients who are at high risk of development of HCC will facilitate early detection and better management.
Aim of the work is to investigate the distribution of cyclin D1 gene G 870A genotype among patients with HCV or HBV infected patients and its relation to HCC. [15] .
PATIENTS AND METHODS
Full history was taken and physical examination were done for the patients and control subjects, laboratory measurements including CBC, liver function tests, serum creatinine, PT, INR, fasting and post prandial serum glucose level.
HBs Ag was assessed using an immunoassay, HCV Ab by 3 rd generation ELISA, HCV RNA by (PCR-RFLP).
Collection of samples was performed by taking 2ml of peripheral venous blood from each subjects under complete aseptic conditions and collected with dipotassium EDTA (1mg/mL) for DNA extraction and analysis of gene polymorphism, all samples were frozen at-20 o C until use.
DNA extraction and genotyping:
Genomic DNA was isolated from dipotassium EDTA (1mg/ml) by standard proteinase k digestion and followed by phenol-chloroform methods by using protocols by genetic blood genomic DNA purification kit (provided by fermentas) according to manufacturer's instruction.
The CCND1 G870A genotype was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis to determine the genotype of G/A polymorphism of CCND1 gene at nucleotide 870 [16] by using specific primer sets as follow: forward 5/GTG AAG TTC ATT TCC AAT CCG C-3' in exon4 reverse 5'/CGG ACA TCA CCC TCA CTT AC-3' in interon 4.
Polymerase chain reaction restriction fragment length polymorphism analysis:
The PCR was performed in a volume of 50l reaction containing 25l of 2xTaq PCR master mix, 10p, 1g template DNA, 0.1-1.0M of each primer and to 50 water, nuclease-and then PCR cycling amplification were 10min. at C. for 7 min. after confirmation of successful PCR amplification by 1.5% agarose gel electrophoresis, each PCR product was digested after incubation at 37 o C for 3 hours with 25l endonuclease SCRF1 enzyme (from streptococcus cremoris F) were purchased from (Roche-applied-science, Germany) to ingest the amplified DNA according to the manufacture's instruction. Digested fragments were exposed to electrophoresis on 3% agarose gel containing 0.5g/ml ethilium bromide and visualized under UV illumination. PCR products with G at the polymorphic site were digested into two fragments 145 bp and 22bp while those with A were not because of the absence of a SCRFI restriction site. Sample yielding 145bp and 22bp fragments were scored as GG, those with single 167bp fragments as AA and 167bp and 22bp as GA. Detection of the digested samples by electrophoresis using submarine gel electrophoresis system (Pharmacia Biotech by SEMKO AB, Sweden) and submarine chamber (Maxicell, EC360, M-E-C apparelus Co. Florida, USA). Photographed under ultraviolet transillumination.
Heralab GmbH laborgreate transilluminator, Germany).
Statistical analysis SPSS 17.0 for windows (SPSS, Chicago, IL) was used to analyze data. Genotype and allele frequencies were compared between HCC patients and controls and also between HCV between without HCC patients using the x2 test. Probabilities (P) were considered statistically significant if P-value <0.05.
RESULTS
This study included 90 HCV positive patients with HCC (60 males and 30 females), 90 HCV positive patients without HCC (64 males and 26 females) and 90 healthy control subjects (52 males and 38 females). There was no significant difference in mean age between the three studied groups. Moreover, there was no significant difference between the groups regarding sex or smoking status. However, there was a significant difference between the groups regarding presence of absence of DM (P<0.001) ( Table 1 ).
There were no significant difference between HCV positive patients with HCC and HCV positive patients without HCC regarding Child Pugh classification (Table 2 , Fig. 1 ).
Analysis of CCND1 gene polymorphism among HCV positive patients with HCC and healthy controls (Table 3) revealed that the GA and AA genotypes were significant more frequent in patients with HCC, than in health controls (41.1% vs 33.3%, P= 0.001 and 38.9% vs 13.3%, P<0.001 respectively). Patients with HCC also had higher frequencies of the allele A than controls (59.4% vs 30%, (P<0.001).
Analysis of the CCND1 gene polymorphism among HCV positive patients with HCC and HCV positive patients without HCC (Table 4) revealed that the GA and AA genotype were significantly more frequent in patients with HCC, than in patients without HCC (41.1% vs 34.4%, P= 0.019 and 38.9% vs 24.4%, P= 0.003 respectively). Patients with HCC also had higher frequencies of the allele A than patients without HCC (59.4% vs 41.7%, P= 0.001). This study included 270 Egyptian persons their ages range from 28-77 years old with mean age of 52.5 years. Although age is a surrogate of duration of infection in many patients thereby, predicting a risk of HCC. In our study age was not significant between the three groups ( Table  1) . These results go in hand with a previous study [19].
In every geographical area, men are more often affected by HCC than women, with higher rates of liver cancer in men having been long interpreted in sex related differences in the exposure to environmental factors known to be carcinogenic to the liver. Also gender differences could also reflect differences in interleukin 6 (IL-6) productions by the liver [23].
Our study included 176 males (65.2%) {60 were HCV +ve with HCC, 64 were HCV +ve and 52 were controls} and 94 females (34.8%) {30were HCV +ve with HCC, 26 were HCV +ve and 38 were controls} (Table 1 ). There was no significant difference in gender between the three groups. These results were in accordance with a study found that there was no significant difference between study groups as regard the gender [21].
Our study does not match with a study reported that males are at higher risk of HCC than females but the difference was not significant [24] . In our study, the frequencies of cyclin D1 genotypes revealed an increase of GA and AA genotypes in HCC patients as compared to control group (Table 4) . Also individuals with GA genotype had three fold risks to develop HCC while those with AA genotype had nine fold risks to develop HCC (Table 4) .
Furthermore, the study showed that there is significant difference between HCC and control groups as regard type of allele (Table 4 ) and A allele increases the risk of developing HCC by 3.4 folds ( Table 4) .
Similar results were obtained by a study reported that CCND1 G870A genotypes increase risk of HCC significantly in Turkish population [21] . These results do not match with a previous study found that the CCND1 G870A genotypes were not associated with HCC susceptibility in Taiwan population [22].
Also our study found that GA and AA genotypes increase risk of HCC significantly by 2.2 folds and 3 folds respectively (compared with GG genotype) moreover our results suggested that the A allele has a dose effect in increasing HCC as risk increased from 2.2 folds for GA genotype to 3 folds to AA genotype supporting the hypothesis that this polymorphism is an individual susceptibility factor in the molecular progression of HCC (Table 4) .
Furthermore, the study showed that there is significant difference between HCV +ve with HCC and HCV +ve without HCC groups as regard type of allele (Table 5 ) and A allele increases the risk of HCC significantly by two folds (Table 5) .
CONCLUSION
It could be concluded that, CCND1 G870 A polymorphism increases the risk of HCC .The A allele has a cumulative dose effect as the risk of HCC increases in individuals of AA genotype more than individuals of GA genotype when we used GG genotype as a reference.
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